FEBRUARY 28, 2018
(SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it had been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN brings together dozens of institutions to help accelerate the translation of biomarker information into clinical applications and to evaluate new ways of testing cancer in its earliest stages and for cancer risk.
“Collaboration with National Cancer Institute’s Early Detection Research Network is an important step in the development of CyPath © Lung, our non-invasive, early lung cancer test. EDRN also offers valuable resources to advance our promising oncological diagnostics
for prostate and bladder cancers,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “EDRN and its members share many of our objectives including
acceleration for testing of promising technologies for early detection of cancer and promoting collaboration among academic and industrial leaders to advance the clinical application of tests such as CyPath © Lung for early cancer detection.”
bioAffinity Technologies’ Executive Vice President Vivienne Rebel, PhD, MD, and Director of Operations Xavier Reveles, MS GC(ASCP) cm will attend next week’s 10th EDRN Scientific Workshop from March 6-8, 2018 in Bethesda, MD that focuses on standards and regulatory science, novel technologies for precision detection, imaging, clinical and validation science, alliances and consortia on biomarkers, and non-profit foundations support for biomarkers.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics
using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas San Antonio. The Company’s initial product is CyPath® Lung, a diagnostic assay for the detection of early-stage lung cancer.
